QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
LON:AVCT

Avacta Group - AVCT Share Forecast, Price & News

GBX 115.20
+2.20 (+1.95%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
110.89
116.59
50-Day Range
97
127.97
52-Week Range
38
146
Volume
576,365 shs
Average Volume
1.90 million shs
Market Capitalization
£294.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AVCT stock logo

About Avacta Group (LON:AVCT) Stock

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Avacta Group Stock Performance

LON:AVCT opened at GBX 115.20 ($1.39) on Tuesday. The company has a current ratio of 7.95, a quick ratio of 7.05 and a debt-to-equity ratio of 4.13. The business's 50 day moving average is GBX 109.99 and its two-hundred day moving average is GBX 123.65. Avacta Group has a 12-month low of GBX 38 ($0.46) and a 12-month high of GBX 146 ($1.76). The stock has a market capitalization of £294.07 million and a price-to-earnings ratio of -10.76.

Receive AVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

AVCT Stock News Headlines

LG Chem Renews License Triggering Payment to Avacta
Avacta full-year results push shares higher
What’s next for the Avacta share price?
UK Stocks Factors to watch on Jan. 10
Avacta Group PLC : Change of auditor
What’s going on with the Avacta share price?
Avacta Group (LSE:AVCT)
Avacta Group PLC : Issue of Equity
Avacta Group Plc (RTQ1.F)
Avacta Signs Diagnostic Licensing Deal with Biokit
See More Headlines
Receive AVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

AVCT Company Calendar

Last Earnings
9/28/2020
Today
8/16/2022
Next Earnings (Estimated)
9/28/2022

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
123
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£2.94 million
Cash Flow
GBX 10.80 per share
Book Value
GBX 16.50 per share

Miscellaneous

Free Float
N/A
Market Cap
£294.07 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. David Alastair Smith
    CEO & Exec. Director
  • Mr. Tony Gardiner (Age 51)
    CFO, Company Sec. & Exec. Director
    Comp: $258k
  • Ms. Emma Wright
    Group In-House Counsel
  • Mr. Michael Vinegrad
    Group Communications Director
  • Dr. Matt Johnson
    Chief Scientific Officer of Diagnostics
  • Dr. Neil Bell (Age 64)
    Chief Devel. Officer of Therapeutics
  • Dr. Fiona McLaughlin FSB (Age 52)
    Ph.D., Chief Scientific Officer of Therapeutics Division
  • Mr. Marc Green
    Head of Product Devel. - Diagnostics
  • Gemma Wilson
    Head of QA/RA - Diagnostics
  • Mr. Petros Sarantos
    Head of Product Management - Diagnostics













AVCT Stock - Frequently Asked Questions

How have AVCT shares performed in 2022?

Avacta Group's stock was trading at GBX 126.40 at the start of the year. Since then, AVCT shares have decreased by 8.9% and is now trading at GBX 115.20.
View the best growth stocks for 2022 here
.

When is Avacta Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 28th 2022.
View our AVCT earnings forecast
.

How were Avacta Group's earnings last quarter?

Avacta Group Plc (LON:AVCT) posted its earnings results on Monday, September, 28th. The biotechnology company reported ($3.74) EPS for the quarter.

What other stocks do shareholders of Avacta Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avacta Group investors own include Legal & General Group (LGEN), SkinBioTherapeutics (SBTX), Augean (AUG), 7digital Group (7DIG), American Airlines Group (AAL), ACI Worldwide (ACIW), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Amyris (AMRS).

What is Avacta Group's stock symbol?

Avacta Group trades on the London Stock Exchange (LON) under the ticker symbol "AVCT."

How do I buy shares of Avacta Group?

Shares of AVCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Avacta Group's stock price today?

One share of AVCT stock can currently be purchased for approximately GBX 115.20.

How much money does Avacta Group make?

Avacta Group (LON:AVCT) has a market capitalization of £294.07 million and generates £2.94 million in revenue each year.

How many employees does Avacta Group have?

The company employs 123 workers across the globe.

How can I contact Avacta Group?

Avacta Group's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The official website for the company is www.avacta.com. The biotechnology company can be reached via phone at +44-1904-217070.

This page (LON:AVCT) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.